Clinton Group’s Theravance Biopharma TBPH Stock Holding History

Clinton Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,993	Closed	-$217K	–	995
2016 Q3	$217K	Buy	+5,993	New	+$167K	0.01%	839

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clinton Group's TBPH Position: Q4 2016 in Review

Clinton Group sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 5,993 shares — an estimated $217K sold.

Clinton Group first reported a position in TBPH in Q3 2016 and held it in 1 quarter. The position peaked at $217K in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

Clinton Group reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
Clinton Group sold 5,993 Theravance Biopharma shares in Q4 2016, an estimated $217K.
Clinton Group first reported a position in Theravance Biopharma in Q3 2016 and held it in 1 quarter.
Clinton Group's Theravance Biopharma position peaked at $217K in Q3 2016.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Clinton Group's 13F filing for Q4 2016, filed 14 Feb 2017.